HCW Biologics regains Nasdaq bid price compliance; will effect 1-for-6 reverse split

HCW Biologics Inc.

Nasdaq Panel confirmed compliance with Bid Price Rule; mandatory monitoring through June 17, 2027.
Company to effect 1-for-6 reverse stock split on June 30, 2026 to maintain compliance.
If non-compliant during monitoring, no additional cure period; may face delisting.
Company now compliant with all Nasdaq continued listing rules.

Featured in Daily 8-K Digest

Selected #5 for 2026-06-30. Read digest

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.